‘CytoDyn Inc. To Host Investment Community Webcast on December 14, 2023\n\nVANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, has announced that Dr. Jacob P. Lalezari, interim Chief Executive Officer, will be hosting an investment community webcast on Thursday, December 14, 2023.\n\nThe webcast will provide an update on the company’s recent comments from the FDA concerning the clinical hold, an anticipated timeline to respond to the FDA and resolve the clinical hold, the company’s next proposed clinical trial, the current approach to business development opportunities, and overall development strategy.\n\nDr. Jacob Lalezari, currently serving as interim CEO, brings over 34 years of industry experience to the company, including nearly 20 years of past experience with leronlimab. He previously served as interim Chief Medical Officer of CytoDyn during 2020, and has been a member of the company’s scientific advisory board for the past several years. Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1996, and also served as the Chief Medical Officer of Virion Therapeutics in 2018. Dr. Lalezari has served as Principal Investigator for Phase I, II, and III clinical studies of new therapies for various viral diseases, including clinical trials conducted by the company.\n\nCytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. The company has studied leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.\n\nThis press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements may include statements about leronlimab, its ability to provide positive health outcomes, the company’s ability to resolve the clinical hold imposed by the U.S. Food and Drug Administration (the “FDA”), the company’s ability to implement a successful operating strategy for the development of leronlimab, the company’s ability to enter into partnerships or collaborations with other companies, the company’s expectations regarding the market for leronlimab, and the company’s ability to successfully commercialize leronlimab.\n\n CytoDyn Inc. Will be hosting an investment community webcast on December 14, 2023 to provide an update on the company’s recent comments from the FDA and its overall development strategy.’

DocuSign Inc's Chief Legal Officer Sells Shares, Raises Questions Among Investors\n\nIn a recent insider transaction, James Shaughnessy, the Chief Legal Officer of DocuSign Inc (NASDAQ:DOCU), sold 3,600 shares of the company on December 13, 2023. This move has caught the attention of market analysts, as insider trades can provide valuable insights into a company's prospects and the sentiment of its top executives.\n\nShaughnessy, a seasoned legal executive with a track record of leadership in the technology sector, is responsible for overseeing DocuSign's legal affairs. This includes compliance, intellectual property, and corporate governance, all crucial aspects in the complex legal landscape of digital transaction management and e-signature solutions.\n\nDocuSign Inc. is a leader in the field of electronic signature and agreement cloud solutions. Its platform enables users to electronically sign and manage agreements with ease and security, serving a wide range of industries. In today's digital world, where remote work and online transactions have become the norm, DocuSign's offerings are essential.\n\nInsider transactions, particularly those involving sales, can be interpreted in various ways. While an insider sell does not necessarily indicate a lack of confidence in the company, it can raise questions among investors. In the case of James Shaughnessy, the insider has sold 3,600 shares over the past year without purchasing any. This one-sided activity might suggest that the insider is taking profits or reallocating personal investments rather than reflecting a negative outlook on the company's future.\n\nIt is also important to consider the broader context of insider transactions at DocuSign Inc. over the past year, there have been no insider buys but nine insider sells.\n\nOn the day of the insider's recent sale, shares of DocuSign Inc. were trading at $55.02, giving the company a market cap of $12.87 billion. This valuation places the stock at a price-earnings ratio of 248.46, significantly higher than the industry median of 26.73 and above the company's historical median price-earnings ratio. Such a high price-earnings ratio could suggest that the stock is overvalued based on earnings, which might partially explain the insider's decision to sell.\n\n When considering the GuruFocus Value (GF Value) of $86.60, DocuSign Inc appears to be modestly undervalued with a price-to-GF-Value ratio of 0.64. The GF Value is an intrinsic value estimate that takes into account historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates. This discrepancy between the high price-earnings ratio and the GF Value suggests that while the stock may seem expensive on an earnings basis, its long-term intrinsic value could be higher than the current market price.\n\n The recent insider sell by DocuSign Inc's Chief Legal Officer has raised questions among investors.